Bausch Health Companies Inc - Company Profile
Powered by 
All the sales intelligence you need on Bausch Health Companies Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bausch Health Companies Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bausch Health Companies Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Bausch Health Companies Inc (Bausch Health) manufactures, develops, and commercializes medical devices, over-the-counter products (OTC), and pharmaceutical products. The company offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, and Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.
Headquarters
Canada
Address
2150 Saint-Elzear Blvd West, Laval, Quebec, H7L4A8
Website
www.bauschhealth.com
Telephone
1 514 7446792
No of Employees
20,300
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BHC (TSE)
Revenue (2024)
$10.3B
6.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
441.3%
(2024 vs 2023)
Market Cap*
$1.8B
Net Profit Margin (2024)
XYZ
418.8%
(2024 vs 2023)
* As of and is in US$
Bausch Health Companies Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Dermatological | Aergel |
| Actinic Keratosis | Akreos |
| Athlete’s Foot | Alaway |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, Bausch Health Canada entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for OKEDI (risperidone prolonged-release suspension for injection) 75 mg and 100 mg. |
| 2026 | New Products/Services | In April, the company announced the launch of the Launch of Biafine, a skin recovery emulsion. |
| 2026 | Regulatory Approval | In April, the company secured a 510(k) clearance from the U.S. Food and Drug Administration for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite Vision Enhancement System. |
Competitor Comparison
| Key Parameters | Bausch Health Companies Inc | Eli Lilly and Co | Amgen Inc | Teva Pharmaceutical Industries Ltd | Viatris Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United States of America | Israel | United States of America |
| City | Laval | Indianapolis | Thousand Oaks | Tel Aviv | Canonsburg |
| State/Province | Quebec | Indiana | California | Tel Aviv | Pennsylvania |
| No. of Employees | 20,300 | 50,605 | 31,500 | 31,173 | 30,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas J. Appio | Director; Chief Executive Officer | Executive Board | 2022 | 64 |
| Jean-Jacques Charhon | Chief Financial Officer | Senior Management | 2024 | 60 |
| Mirza Dautbegovic | Chief Operating Officer; Executive Vice President | Senior Management | 2022 | - |
| Steven H. Lee | Controller; Chief Accounting Officer; Senior Vice President | Senior Management | 2025 | - |
| Kathleen Fitzpatrick | Chief Human Resources Officer; Chief Communications Officer; Executive Vice President | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer